| Hazard Information | Back Directory | [Uses]
Delparantag (PMX-60056) is a salicylamide derivative and an effective unfractionated heparin (UFH) and low molecular weight heparin (LMWH) reversing agent. Delparantag shows ability to neutralize the anticoagulation and bleeding effects of UFH and LMWH[1][2]. | [Definition]
ChEBI: Delparantag is an amidobenzoic acid. | [in vivo]
Delparantag (PMX-60056; 0.5 mg/kg, 1.0 mg/kg, or 2.0 mg/kg; intravenous injection; once; male Sprague-Dawley rats) treatment neutralizes the antithrombotic, anticoagulant, and bleeding effects of heparins as effectively as protamine sulfate and may be slightly more efficacious against LMWHs[2].
Plasma half-life elimination of Delparantag is between 3 and 5 min[1]. | Animal Model: | Male Sprague-Dawley rats (250-275 g) injected with UFH or LMWH (2.0 mg/kg)[2] | | Dosage: | 0.5 mg/kg, 1.0 mg/kg, or 2.0 mg/kg | | Administration: | Intravenous injection; once | | Result: | Neutralizes the antithrombotic, anticoagulant, and bleeding effects of heparins as effectively as protamine sulfate and may be slightly more efficacious against LMWHs.
|
| [References]
[1] Mahan CE. A 1-year drug utilization evaluation of protamine in hospitalized patients to identify possible future roles of heparin and low molecular weight heparin reversal agents. J Thromb Thrombolysis. 2014 Apr;37(3):271-8. DOI:10.1007/s11239-013-0927-7
[2] Kuziej J, et al. In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative. Clin Appl Thromb Hemost. 2010 Aug;16(4):377-86. DOI:10.1177/1076029610366439 |
|
|